Uncategorized
calendar_month Nov 20, 2026

Walmart Gets Bullish Rating Despite Pharmacy Deflation Headwinds

Walmart Inc. (NASDAQ:WMT) shares are recovering on Friday after declining on Thursday following its third-quarter results.

It reported an adjusted EPS of 65 cents, exceeding analyst expectations of 64 cents. The figure excludes an after-tax loss of 3 cents per share related to equity and other investments.

Revenue rose 5.2% year over year to $188.835 billion, topping the consensus estimate of $187.271 billion.

However, Walmart’s weight-loss drug windfall is losing momentum despite rising prescription volumes.

Analyst Price Forecast Revisions

Several analysts raised their price forecasts following Walmart’s third-quarter results and increased guidance, while maintaining their existing ratings.

  • Morgan Stanley analyst Simeon Gutman maintained an Overweight rating and raised his price forecast to $135 from $125.
  • Piper Sandler analyst Peter Keith maintained an Overweight rating and increased his price forecast to $138 from $128.
  • TD Cowen analyst Max Rakhlenko maintained a Buy rating and raised his price forecast to $147 from $125.
  • Truist Securities analyst Scot Ciccarelli maintained a Buy rating and increased his price forecast to $134 from $114.
  • BTIG analyst Robert Drbul reiterated a Buy rating and maintained his $140 price forecast.

BTIG Analyst View

Drbul believes Walmart’s underlying U.S. business remains healthy, although Health & Wellness (H&W) is expected to weigh on reported comparable sales.

Walmart’s 2.9% U.S. comparable sales growth included an approximately 125-basis-point drag from Maximum Fair Price-related pharmacy deflation and brand-to-generic transfers, partly offset by a roughly 60-basis-point contribution from GLP-1 drugs.

Excluding H&W, comparable sales increased 3.6%, slightly accelerating from the second quarter of fiscal 2027 and improving on a two-year basis.

Looking ahead, the analyst expects healthy underlying demand but anticipates continued pressure on reported comparable sales from H&W.

MFP-related headwinds are expected to remain near current levels or increase slightly, while the contribution from GLP-1 drugs is likely to moderate.

However, improving H&W gross profit margins should help cushion the impact of weaker reported sales, according to the analyst.

Earnings Estimates And Outlook

Drbul maintained his fiscal 2027 EPS estimate at $2.90 but lowered his fourth-quarter Walmart U.S. comparable sales growth forecast to 2.9% from 3.1%. He expects comparable sales to increase 3.6% excluding H&W.

The analyst expects fiscal 2027 net sales of $748 billion, representing approximately 6% year-over-year growth, with operating income projected to grow faster than sales.

For fiscal 2028, Drbul raised his EPS estimate to $3.25 from $3.15.

WMT Price Action: Walmart shares were up 2.82% at $129.60 at the time of publication on Friday, according to Benzinga Pro data.

Photo via Shutterstock